cariprazine

Structure in first source

Also Known As:

3-(trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea; N'-(trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-N,N-dimethylurea monohydrochloride; RGH-188; Vraylar; cariprazine HCl; cariprazine hydrochloride; trans-4-(2-(4-(2,3-dichlorophenyl)piperazine-1-yl)-ethyl)-N,N-dimethylcarbamoyl-cyclohexyl-amine hydrochloride

Networked: 262 relevant articles (70 outcomes, 98 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - cariprazine: 262

Experts

1.	Laszlovszky, István: 31 articles (02/2022 - 02/2014)
2.	Németh, György: 30 articles (01/2022 - 02/2014)
3.	Durgam, Suresh: 28 articles (01/2020 - 02/2014)
4.	Earley, Willie: 23 articles (10/2021 - 03/2016)
5.	Kiss, Béla: 19 articles (09/2021 - 11/2011)
6.	Lu, Kaifeng: 18 articles (01/2019 - 03/2015)
7.	Adham, Nika: 17 articles (09/2021 - 03/2013)
8.	Barabássy, Ágota: 15 articles (01/2022 - 01/2017)
9.	Yatham, Lakshmi N: 14 articles (12/2021 - 03/2016)
10.	Vieta, Eduard: 13 articles (02/2022 - 11/2015)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 01/01/2021 - "Open-label, non-controlled study included 60 adult schizophrenia patients (F20 on ICD-10, 49% males) with predominantly negative symptoms (Positive and Negative Syndrome Scale, S factor score for negative and positive symptoms, PANSS-FSNS ≥ 15 and PANSS-FSPS <19) treated with cariprazine (starting daily dose 1.5 mg followed by upward titration by 1.5 mg weekly up to 6 mg if needed) were assessed with PANSS, CAINS (The Clinical Assessment Interview for Negative Symptoms), CDSS (Calgary Depression Scale for Schizophrenia), and SAS (Simpson-Angus Scale for Extrapyramidal Symptoms) scales at baseline and on week 1, 2, and 4. Most patients (75%) improved during 28 days of cariprazine treatment. " 01/01/2023 - "In conclusion, cariprazine, a potent D3-D2 partial agonist has been found to be safe and effective in the treatment of early and late stage schizophrenia." 01/01/2016 - "These findings support very recent results showing efficacy of cariprazine in the treatment of negative symptoms in schizophrenia patients. " 12/29/2018 - "These studies have provided evidence for efficacy of cariprazine in the treatment of schizophrenia exacerbations compared to placebo, with safety and good tolerability. " 03/01/2016 - "In this study, the overall cariprazine treatment effect was not statistically significant, but patients treated with low-dose cariprazine showed significantly greater improvement in schizophrenia symptoms relative to placebo-treated patients. "
2.	Bipolar Disorder (Manic Depressive Psychosis) 01/01/2021 - "Current evidence suggests efficacy for cariprazine 3-12 mg/day in the treatment of acute manic and mixed episodes; for bipolar depression, the efficacy of cariprazine appears to be dose-related, with doses of 1.5-3 mg/day beneficial as monotherapy. " 09/20/2023 - "Efficacy of cariprazine in patients with bipolar depression and higher or lower levels of baseline anxiety: a pooled post hoc analysis." 01/01/2020 - "Factors that may have affected the outcome of the trial were identified, which helped to inform the design and conduct of subsequent phase 2b/3 clinical trials of cariprazine in bipolar depression." 09/01/2019 - "Further phase-3 clinical studies proved the efficacy of cariprazine in the acute treatment of manic or mixed episodes associated with bipolar I disorder, as well as in bipolar depression. " 11/01/2018 - "Four trials evaluated the safety and efficacy of cariprazine in bipolar disorder. "
3.	Mania (Manias) 11/01/2015 - "Results suggest that cariprazine treatment improved mania across YMRS symptoms; a significant percentage of cariprazine- versus placebo-treated patients had mild/no symptoms at the end of treatment." 10/01/2019 - "Efficacy of cariprazine compared to placebo was assessed (Week 3) by Young Mania Rating Scale (YMRS) and MADRS scores and rates of mania response and remission. " 01/01/2020 - "A phase II study looked at the use of cariprazine in mania or mix states and showed cariprazine significantly decreased YMRS scores compared to placebo, least-square mean difference of -6.1 (p < 0.001). " 10/01/2019 - "Herein, patients were pooled from three similarly-designed pivotal trials of cariprazine compared to placebo for BP-I mania (NCT00488618/NCT01058096/NCT01058668) in post hoc analyses of mixed features using three criteria: ≥3 DS (DSM-5), ≥2 DS, and Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥10. " 10/01/2019 - "Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials."
4.	Psychotic Disorders (Schizoaffective Disorder) 02/28/2023 - "He was successfully treated with cariprazine monotherapy, which culminated in the remission of his both positive and negative symptoms of psychosis as well as in the marked improvement in social functioning. " 01/01/2020 - "Conclusions: Cariprazine may be well tolerated and effective for pediatric bipolar and psychotic disorders; however, compared with higher doses, total daily doses ≤3 mg/day appear to be more tolerable. " 01/01/2022 - "The authors suggest that cariprazine may be effective in the treatment of psychosis in a broader sense and should be considered a first-line treatment option." 01/01/2023 - "This pilot study suggests that cariprazine is a safe and effective treatment in early psychosis, particularly for the alleviation of negative symptoms which remains an area of unmet treatment need." 01/01/2023 - "To evaluate the efficacy of cariprazine for negative symptoms in early psychosis patients. "
5.	Major Depressive Disorder (Major Depressive Disorders) 11/01/2018 - "Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial." 01/01/2023 - "Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study." 01/01/2018 - "Cariprazine is also approved in the US for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and is being studied for the treatment of bipolar I depression and major depressive disorder." 01/01/2019 - "Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder." 01/01/2021 - "Cariprazine is currently approved for the treatment of patients with schizophrenia (USA and EU), and for manic, depressive, and episodes with mixed features in bipolar I disorder (USA): several randomized controlled studies have also explored its efficacy in patients with major depressive disorder. "

Related Drugs and Biologics

1.	Antipsychotic Agents (Antipsychotics)
2.	Dopamine (Intropin)
3.	Aripiprazole (Abilify)
4.	Antidepressive Agents (Antidepressants)
5.	Risperidone (Risperdal Consta)
6.	5-HT1A Serotonin Receptor
7.	Lurasidone Hydrochloride
8.	Olanzapine (Zyprexa)
9.	Quetiapine Fumarate (Seroquel)
10.	Clozapine (Clozaril)

Related Therapies and Procedures

1.	Therapeutics
2.	Secondary Prevention
3.	Self Administration (Administration, Self)
4.	Drug Therapy (Chemotherapy)
5.	Aftercare (After-Treatment)